aTyr Pharma, Inc. (LIFE) financial statements (2022 and earlier)

Company profile

Business Address 3545 JOHN HOPKINS COURT, STE #250
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments107,91131,68931,14449,54585,11972,14795,535
Cash and cash equivalents2,33616,9529,21022,96221,09138,38853,025
Short-term investments105,57514,73721,93426,58364,02833,75942,510
Receivables4352,039     
Prepaid expense5,2231,803     
Other undisclosed current assets  7811,2581,8662,6212,415
Total current assets:113,56935,53131,92550,80386,98574,76897,950
Noncurrent Assets
Operating lease, right-of-use asset1,2672,0832,821
Property, plant and equipment5438991,2701,8532,2801,4211,793
Long-term investments and receivables     4,00229,814
Long-term investments     4,00229,814
Other noncurrent assets1582131729090333118
Total noncurrent assets:1,9683,1954,2631,9432,3705,75631,725
TOTAL ASSETS:115,53738,72636,18852,74689,35580,524129,675
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,0335,0033,2233,0665,3798,0568,467
Accounts payable1,0311,4318471,0402,2762,6063,872
Accrued liabilities4,0023,5722,3762,0263,1035,4504,595
Deferred revenue  208
Debt  9,4927,7675,0123393,366
Deferred revenue and credits 130315
Other undisclosed current liabilities980861     
Total current liabilities:6,0135,86412,92310,83310,3918,52512,148
Noncurrent Liabilities
Long-term debt and lease obligation3981,3782,2398,26314,7199,1981,776
Long-term debt, excluding current maturities   8,26314,7199,1981,776
Operating lease, liability3981,3782,239
Liabilities, other than long-term debt      701
Deferred revenue and credits  130
Other liabilities      571
Other undisclosed noncurrent liabilities(398)(1,378)     
Total noncurrent liabilities:3981,3782,2398,26314,7199,1982,477
Total liabilities:6,4117,24215,16219,09625,11017,72314,625
Stockholders' equity
Stockholders' equity attributable to parent109,30131,65021,18633,65064,24562,801115,050
Preferred stock  222  
Common stock2811431302424
Additional paid in capital481,832370,210343,524332,378328,519278,832273,321
Accumulated other comprehensive loss(263)(43)(40)(60)(120)(76)(171)
Accumulated deficit(372,296)(338,528)(322,304)(298,701)(264,186)(215,979)(158,124)
Stockholders' equity attributable to noncontrolling interest(175)(166)(160)    
Total stockholders' equity:109,12631,48421,02633,65064,24562,801115,050
TOTAL LIABILITIES AND EQUITY:115,53738,72636,18852,74689,35580,524129,675

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues 10,455422    
Gross profit: 10,455422    
Operating expenses(34,015)(26,366)(23,400)(32,820)(47,145)(57,940)(47,616)
Operating loss:(34,015)(15,911)(22,978)(32,820)(47,145)(57,940)(47,616)
Nonoperating income (expense)238(319)(785)(1,695)(1,062)36(357)
Other nonoperating income (expense)   (1,695)(1,062)36(357)
Interest and debt expense     (29) 
Loss from continuing operations before equity method investments, income taxes:(33,777)(16,230)(23,763)(34,515)(48,207)(57,933)(47,973)
Other undisclosed income from continuing operations before income taxes3    29 
Loss from continuing operations before income taxes:(33,774)(16,230)(23,763)(34,515)(48,207)(57,904)(47,973)
Income tax benefit     49 
Loss before gain (loss) on sale of properties:(33,774)(16,230)(23,763)(34,515)(48,207)(57,855)(47,973)
Other undisclosed net loss(3)      
Net loss:(33,777)(16,230)(23,763)(34,515)(48,207)(57,855)(47,973)
Net income attributable to noncontrolling interest96160    
Net loss attributable to parent:(33,768)(16,224)(23,603)(34,515)(48,207)(57,855)(47,973)
Preferred stock dividends and other adjustments      (15)
Net loss available to common stockholders, diluted:(33,768)(16,224)(23,603)(34,515)(48,207)(57,855)(47,988)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(33,777)(16,230)(23,763)(34,515)(48,207)(57,855)(47,973)
Other undisclosed comprehensive income (loss)(220)(3)20    
Comprehensive loss:(33,997)(16,233)(23,743)(34,515)(48,207)(57,855)(47,973)
Comprehensive income, net of tax, attributable to noncontrolling interest96160    
Other undisclosed comprehensive income (loss), net of tax, attributable to parent   60(44)95(171)
Comprehensive loss, net of tax, attributable to parent:(33,988)(16,227)(23,583)(34,455)(48,251)(57,760)(48,144)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: